aTYR PHARMA INC (ATYR): Total Assets
$93.00M
As of 2025-12-31
$69.83M
As of 2026-06-30
-1.0%
3-year compound annual growth
+19.2%
5-year compound annual growth
-3.3%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $93.00M | -4.0% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $96.83M | -19.7% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $120.65M | +26.0% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $95.79M | -17.1% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $115.54M | +198.3% | 2023-03-14, Balance as of period end |
| 2020-12-31 | $38.73M | +7.0% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $36.19M | -31.4% | 2021-03-24, Balance as of period end |
| 2018-12-31 | $52.75M | -41.0% | 2020-03-26, Balance as of period end |
| 2017-12-31 | $89.36M | +11.0% | 2019-03-26, Balance as of period end |
| 2016-12-31 | $80.52M | -37.9% | 2018-03-20, Balance as of period end |
| 2015-12-31 | $129.68M | +528.1% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $20.64M | n/a | 2016-03-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $93.00M | -4.0% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $1.64M | +195.7% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $7.39M | -49.6% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $5.78M | -32.8% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $61.88M | -36.3% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $32.35M | -18.2% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $152.98M | +860.8% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $15.99M | +70.3% |
| Prokidney Corp. (PROK) | 2025-12-31 | $335.57M | -23.9% |
Compare ATYR, ZIVO, VIVS, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗